Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Type 2 Diabetes Clinical Trial

Official title:

An Open-label, Randomized,Three-way Cross-over, Single Dose Study to Explore the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02386943
• Other study ID #: CCEMD022
• Status: Recruiting
• Phase: Phase 4
• First received: March 7, 2015
• Last updated: March 11, 2015
• Start date: December 2013
• Est. completion date: March 2015

Study information

• Verified date: March 2015
• Source: Shanghai Jiao Tong University School of Medicine
• Contact: Guang Ning, MD. PHD
• Phone: +86021-64370045
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to explore the effects of two DPP-4 inhibitors(Sitagliptin, Saxagliptin) on β- and α-cell function, as well as the incretin effect.

Description:

The study is an open-label, randomized, three-way crossover and single-dose study.Subjects with newly onset T2DM are enrolled. They are assigned to take a single dose of sitagliptin (100 mg), saxagliptin (5 mg), or blank control in a randomized order separated by a washout period of 7-14 days.Then the two-step hyperglycemic clamp is initiated.

On each experimental day, the subject will take the given dose of Sitagliptin, Saxagliptin and nothing for blank control two hours before the clamp experiment starts.

The hyperglycaemic clamp will be performed after an overnight fast. Subjects will be placed in a recumbent position and cannula will be inserted in a dorsal hand vein. The hand will be placed in a heating box (50℃) throughout the experiment to allow frequent sampling of arterialized blood. A second cannula will be inserted in a contralateral cubital vein for glucose infusion.

At time zero (0 min), a 50% glucose bolus will be injected during 1 min to increase PG to 15mM. The glucose bolus will be calculated as:(15mM-FPG)×35 mg glucose × body weight (kg). PG will be measured bedside every 5 min and maintained at 15mM by an adjustable continuous 20% glucose infusion. After 90min, PG will be lowered down to 7mM for the islet cells to rest, then the subject will be instructed to consume 75g glucose solution orally in 5min. 40min after the oral glucose consumption, the 90min-hyperglycaemic clamp experiment wil be restarted. The oral period of hyperglycaemic clamp process is the same as what's done in fasting period. Blood samples will be collected in -2h, 0min, 10min, 90min in both hyperglycaemic clamp experimental process for the measurement of insulin, c-peptide, glucagon, active GLP-1 and other incretin hormones.

Thus we could evaluate the beta cell function represented by the first phase and the second phase of insulin secretion(C-peptide secretion) and alpha cell function represented by the change of glucagon concentration during the fasting period and oral period of hyperglycaemic clamp experiment and the change of active GLP-1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

1. 40-60 years old;

2. Diagnosed as T2DM according to the 1999 World Health Organization criteria within 2 years;

3. Free of any antihypoglycemia therapy ever;

4. No weight fluctuation greater than 5% in late 3 months.

5. Understand and voluntarily sign an informed consent document.

6. Good study compliance.

Exclusion Criteria:

1. With any significant medical condition (within 3 years), laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study;

2. Used any prescribed systemic or topical medication within 30 days of the first dose administration;

3. Any medical or surgical conditions possibly affecting study drug absorption, distribution, metabolism and excretion;

4. Participated in a clinical study involving administration of an investigational drug within 90 days preceding the first dose administration or within five half-lives of the first dose administration (whichever is longer);

5. Donated blood or plasma or had any other significant blood loss within 2 months preceding the first dose administration;

6. History of multiple drug allergies;

7. Any clinically significant allergic disease;

8. Recently drug or alcohol abuse (>35 unit/week, 1 unit=8g alcohol @ 1 standard drink @ 250ml beer @ 140ml wine @ 25ml strong alcohol drink like whiskey); Smokers or users of other tobacco products in the 3 months prior to screening.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Type 2 Diabetes

Intervention

Drug:
• Sitagliptin
100mg po once.
• Saxagliptin
5mg po once.
• Blank control
No medication is taken.

Locations

Country	Name	City	State
China	Shanghai Jiao Tong University School of Medicine	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ß-cell function (measurement of insulin and c-peptide during the clamp study)	The primary endpoints are the effects of DPP-4 inhibitors on ß-cell function, with the measurement of insulin and c-peptide during the clamp study.	15 months	No
Secondary	a-cell function (measurement of glucagon during the clamp study)	The secondary endpoints are the effects of DPP-4 inhibitors on a-cell function, with the measurement of glucagon during the clamp study.	15 months	No
Secondary	Incretin effect (measurement of active GLP-1 during the clamp study)	The secondary endpoints are the effects of DPP-4 inhibitors on incretin effect, with the measurement of active GLP-1 during the clamp study.	15 months	No